Chronic Monotherapy With Rosuvastatin Prevents Progressive Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure
Valerio Zacà, MD,
Sharad Rastogi, MD,
Makoto Imai, MD,
Mengjun Wang, MD,
Victor G. Sharov, PhD,
Alice Jiang, MD,
Sidney Goldstein, MD, FACC and
Hani N. Sabbah, PhD, FACC*
Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute, Henry Ford Health System, Detroit, Michigan.
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Ventriculographic Measures of LV Function and Size
Bar graphs depicting change ( ) in left ventricular (LV) ejection fraction (EF), LV end-diastolic volume (EDV), and LV end-systolic volume (ESV) between pretreatment and post-treatment in control dogs, dogs randomized to low-dose (LD) rosuvastatin (RSV), or dogs randomized to high-dose (HD) RSV. *p < 0.05 versus control group;  p < 0.05 versus LD RSV.
|
|
View larger version (9K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Magnitude of Circulating BMSCs
Absolute number of circulating Sca-1–positive bone marrow-derived stem cells (BMSCs). *p < 0.05 versus control animals; p < 0.05 versus normal (NL). Abbreviations as in Figure 1.
|
|
|
and MMP-2
p < 0.05 versus LD RSV. Abbreviations as in Figure 1.